tradingkey.logo

Deals of the day-Mergers and acquisitions

ReutersFeb 11, 2025 2:43 PM

- The following bids, mergers, acquisitions and disposals were reported by 1430 GMT on Tuesday:

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's BX.N drug development unit, for up to $3.1 billion, to boost its cardiovascular business.

nL8N3P20AT

Novonesis said that it had agreed to buy the stake of its partner, Swiss-Dutch chemical manufacturer DSM-Firmenich, in their joint enzymes venture for 1.5 billion euros ($1.55 billion).

nL8N3P20AB

Canada's Toronto-Dominion Bank said it would sell 165.4 million shares in Charles Schwab for $79.25 per share.

nL4N3P20BH

Singapore's Paragon REIT said it received a buyout offer from its major shareholder, Cuscaden Peak, and parties valuing the real estate firm at S$2.78 billion ($2.05 billion).

nL4N3P11XE

Merck KGaA MRCG.DE, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics .

nL1N3P119V

Afore Insurance Services has acquired Franklin, Tennessee-based Broussard and Associates, Inc, operating as Innovative Insurance Services.

nL6N3P10QF

Emerson Electric said on Monday that its $265 per-share offer to acquire Aspen Technology was its "best and final" price.

nL4N3P11K6

Fox Corp said on Monday it has purchased Red Seat Ventures, the digital media company whose clients include former Fox News stars Megyn Kelly and Tucker Carlson, in a bid to tap younger audiences and the growing podcast market.

nL4N3P119G

Hub International Limited has acquired the assets of St. Louis, Missouri-based Yavitz Insurance Group.

nL6N3P10K3

FactSet FDS.N said on Monday it has acquired trade management platform LiquidityBook in an all-cash deal valued at $246.5 million as the financial data services firm seeks to provide more consolidated solutions to its clients.

nL4N3P10VS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI